Actively Recruiting
Study of Maribavir Safety and Effectiveness in Chinese Adults with Cytomegalovirus Infection After Stem Cell or Organ Transplant
Led by Takeda · Updated on 2026-03-02
20
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of maribavir in Chinese adults who have received hematopoietic stem cell or organ transplants and have cytomegalovirus CMV infections that are resistant or unresponsive to standard treatments. The study also aims to understand the recurrence rate of CMV after maribavir treatment and monitor for viral mutations that could cause resistance to the drug. Participants will take maribavir tablets orally, 400 mg twice daily, for up to 8 weeks. The study is open-label and single-arm, meaning all participants receive maribavir without placebo comparison. Treatment effects and drug levels in the body will be closely observed during and after the treatment period. During the study, participants will visit the clinic 18 times for evaluations including vital signs, laboratory tests, and electrocardiograms. Researchers will track side effects, blood levels of the virus, symptom control, and any return of infection up to 20 weeks from starting the drug. The study also includes detailed blood sampling to measure how maribavir is processed in the body.
CONDITIONS
Brief Title
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
